Revolutionizing
Preclinical R&D
Discover how BenchSci’s preclinical R&D platform, ASCEND, is changing the way scientists decode disease biology at scale.
Advance Your Research
Reach key milestones sooner with an optimized experimental path. Use patented machine learning technology to search, analyze, and extract scientific evidence from a comprehensive catalog of biomedical literature in minutes, not months.
Improve R&D Productivity
Increase throughput and be more efficient with your resources. Pursue only those approaches with the highest chance for success.
De-risk Your Portfolio
Focus on promising targets and indications, while identifying safety and efficacy risks for clinical translation. Build confidence in project strategies or support alternative avenues.
Why Drug Discovery Needs BenchSci
90%
Investigational New Drugs (INDs) that fail in clinical trials.
$500M+
Spendings per big pharma, per year, on preclinical R&D.
79.5%
Experiments that fail, are redundant, or are irreproducible.
The platform is really, really useful—we save a lot of time and energy, and it’s helpful to communicate between us.
Without the platform, it would have taken me hours to find the antibody I needed, but with it, it took me a few minutes.
The quality of the data is the number one value-add. I can narrow the field down to 2 or 3 candidates, compared to 10 or 20
Industry scientist at top 20 pharma
It would have been absolutely impossible to find a commercially available antibody for our experiment without the platform
Industry scientist at top 20 pharma
- Industry scientist at top 20 pharma
- Industry scientist at top 20 pharma
- Industry scientist at top 20 pharma
- Industry scientist at top 20 pharma
new logo garden goes here
Lorem ipsum dolor sit amet consectetur.
